Sage Journals: Discover world-class research

Abstract

B cell dysfunctionand pathogenicautoantibodyformationare thoughtto be criticalin the pathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonalantibody(MAb) specific for human CD20, rituximab, for the treatment of patients with SLE.

Keywords

anti-CD20 rituximab systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Tedder TF , Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes . Immunol Today 1994; 15: 450-544 .

Grillo-Lopez A. Rituximab: an insider’s historical perspective . Semin Oncol 2000; 6(Suppl 12): 9-16 .

Hainsworth JD , Burris HA , Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma . Blood 2000; 95: 3052-3056 (abstract).

Solal-Celigny P , Salles G , Brousse N et al. Rituximab as first-line treatment of patients with follicular lyphoma and a low-burden tumor: clinical and molecularevaluation . Blood 1999;94(Suppl1): 631-631 abstract.

Gutheil JC , Finucane D , Rodriguez R , Saleh F , Stahler S , Royston I. Phase II study of rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin’s lymphoma . Proc ASCO 2000; 19: 22a-22a abstract.

Stasi R , Pagano A , Stipa E , Amadori S. Rituxiamb chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopaenic purpura . Blood 2001; 98: 952-957 .

Saleh MN , Gutheil J , Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopaenia . Semin Oncol 2000; 27(Suppl 12): 99-103 .

Perotta A , Sunneberg TA , Scott J et al. Rituxan in the treatment of chronic idiopathic thrombocytopaenic purpura (ITP) . Blood 1999; 94: 49-49 (abstract).

Zaia F , Iacona I , Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia . Haematolgica 2002; 87: 189-195 .

10.

Ratanatharathorn V , Carson E , Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopaenia in a patient with chronic graft-versus-host disease . Ann Int Med 2000; 133: 275-279 .

11.

Perrotta S , Locatelli F , La Manna A , Cennamo L , De Stefano P , Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening haemolytic anaemia in a patient with systemic lupus erythematosus . J Haematol 2002; 116: 465-467 .

12.

Janossy G , Duke O , Poulter LW , Panayi G , Bofill M , Goldstein G. Rheumatoid arthritis: a disease of T lymphocyte-macrophage immunoregulation . Lancet 1981; 2: 839-842 .

13.

Edwards JC , Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B cells . Rheumatology 2001; 40: 205-211 .

14.

Leandro MJ , Edwards JC , Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated for B lymphocyte depletion . Ann Rheum Dis 2002; 61: 883-888 .

15.

Cambridge G , Leandro MJ , Edwards JCW , Ehrenstein MR , Salden M , Webster D. B lymphocyte depletion in patients with rheumatoid arthritis: serial studies of immunological parameters . Arthritis Rheum 2002; 46(Suppl 9): S1350-S1350 .

16.

Stahl HD , Szczepanski, Szechinski J et al. Rituximab in RA: efficacy and safety from a randomized controlled trial . Ann Rheum Dis 2003; 62(Suppl 1): OP004-OP004 .

17.

Edwards JCW , Szczepanski L , Szechinski J et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomised, placebo-controlled trial in patients with rheumatoid arthritis . Arthritis Rheum 2002; 46(Suppl 9): S446-S446 .

18.

Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis . Arthritis Rheum 2002; 46(Suppl 9): S1299-S1299 .

19.

De Vita S , Zaja F , Sacco S et al. Efficacy and safety of rituximab in type II mixed essential cryoglobulinaemia . Arthritis Rheum 2002; 46(Suppl 9): S469-S469 .

20.

Specks U , Fervenza FC , McDonald TJ , Hogan MCE. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy . Arthritis Rheum 2001; 44: 2836-2840 .

21.

Isenberg D , Leckie MJ. Biological treatments for systemic lupus erythematosus . Scand J Rheumatol 2002; 31: 1-5 .

22.

Dean GS , Tyrell-Price J , Crawley E , Isenberg DA. Cytokines and systemic lupus erythematosus . Ann Rheum Dis 2000; 59: 243-251 .

23.

Mason LJ , Isenberg DA. The immunopathogenesis of SLE . In Gladman DD, Hockberg MC eds. Balliere’s Clinical Rheumatology 1998; 12: 385-403 .

24.

Levine TD , Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab . Neurology 1999; 52: 1701-1704 .

25.

Davas EM , Tsirogianni A , Kappou I , Karamitsos D , Economidou I , Dantis PC. Serum IL-6, TNF alpha, p55 srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus . Clin Rheumatol 1999; 18: 17-22 .

26.

Tokano Y , Morimoto S , Kaneko H et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) - relation to Th1- and Th2-derived cytokines . Clin Exp Immunol 1999; 116: 169-173 .

27.

Llorente L , Richard-Patin Y , Wijdenes J et al. Spontaneous production of IL-10 by B lymphocytes and monocytes in systemic lupus erythematosus . Eur Cytokine Netw 1993; 4: 421-427 .

28.

Houssian FA , Lefebvre C , Vanden Berghe M , Lambert M , Devogelaer JP , Renauld JC. Serum IL-10 titres in systemic lupus erythematosus reflect disease activity . Lupus 1995; 4: 393-395 .

29.

Liu TF , Jones BM. Impaired production of IL-12 in systemic lupus erythematosus . Cytokine 1998; 10: 140-147 .

30.

Emilie D , Mariette X.

Interleukin 10: a new therapeutic target in systemic lupus erythematosus?

Joint Bone Spine 2001; 68: 4-5 .

31.

Min DJ , Cho ML , Cho CS et al. Decreased production of IL-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus . Scand J Rheumatol 2001; 30: 159-163 .

32.

Rathmell JC , Fournier S , Weintraub BC , Allison JP , Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells . J Exp Med 1998; 188: 651-659 .

33.

Linnik M , Staines NA , Berden J , Isenberg DA. Workshop report on some new ideas about the treatment of systemic lupus erythematosus . Lupus 2002; 11: 793-796 .

34.

Anolik JH , Campbell D , Felgar RE et al. The relationship of Fcg RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus . Arthritis Rheum 2003; 48: 455-459 .

35.

Anolik JH , Campbell D , Felgar RE , Rosenblatt J , Young F , Looney RJ. B lymphocyte depletion in the treatment of systemic lupus erythematosus . Arthritis Rheum 2002; 46(Suppl 9): S717-S717 .

36.

Leandro MJ , Edwards JC , Cambridge G , Ehrenstein MR , Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus . Arthritis Rheum 2002; 46: 2673-2677 .

37.

Leandro MJ , Ehrenstein MR , Edwards JCW , Manson J , Cambridge G , Isenberg DA. Treatment of refractory lupus nephritis with B lymphocyte depletion . Arthritis Rheum 2003; 48(Suppl 9): S924-S924 .

38.

Reff ME , Carner K , Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 . Blood 1994; 83: 435-445 .

39.

Anolik JH , Barnard J , Cappione A et al. Effects of rituximab on B cells in human SLE . Arthritis Rheum 2003; 48(Suppl 9): S594-S594 .

40.

Leandro MJ , Edwards JCW , Cambridge G , Ehrenstein MR. B cell repopulationoccurs mainly from naïve B cells in patient with rheumatoid arthritis and systemic lupus erythematosus . Arthritis Rheum 2003; 48(Suppl 9): S1160-S1160 .

41.

Quartier P , Brethon B , Phillippet P , Landman-Parker J , Le Deist F , Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab . Lancet 2001; 358: 1511-1513 .

42.

Zecca M , De Stefano P , Nobili B , Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia . Blood 2001; 97: 3995-3997 .

43.

Damiani D , Silvestri F , Fanin R , Baccarani M. Rituximab in a case of cold agglutinin disease . Br J Haematol 2001; 114: 229-234 .

44.

Berentsen S , Tjonnfjord GE , Brudevold R et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease . Br J Haematol 2001; 115: 79-83 .

45.

Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20- positive, low-grade non-Hodgkin’s lymphoma . Br J Haematol 2001; 112: 1083-1090 .

46.

Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukaemia . Blood 2002; 99: 1092-1094 .

47.

Auner HW , Wolfer A , Beham-Schmid C , Strunk D , Linkesch W , Sill H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired red cell aplasia refractory to conventional treatment . Br J Haematol 2002; 116: 725-728 .

Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?

Abstract

Keywords

Get full access to this article

References